Enanta Pharmaceuticals | Frais De Vente Et D'Administration

Selling And Administration Expenses Changement Date
AbbVie USD 3.61B 273M 2023-12
Amgen USD 1.76B 424M 2023-12
Arrowhead Research USD 26.19M 595K 2023-12
AstraZeneca USD 3.91B 194M 2023-09
Biogen USD 608.5M 179.7M 2023-12
Bristol-Myers Squibb USD 2.06B 126M 2023-12
Gilead Sciences USD 1.61B 293M 2023-12
GlaxoSmithKline GBP 2.18B 6M 2023-09
Halozyme Therapeutics USD 37.61M 2.34M 2023-12
Incyte USD 293.86M 25.97M 2023-12
Insmed USD 89.53M 1.1M 2023-12
Ionis Pharmaceuticals USD 71.01M 1.06M 2023-12
Ligand Pharmaceuticals USD 15.99M 1.34M 2023-12
Merck USD 2.75B 272M 2023-12
Neurocrine Biosciences USD 204.2M 17.6M 2023-09
Pfizer USD 4.47B 1.27B 2023-12
PTC Therapeutics USD 76.29M 4.6M 2023-12
Roche Holding CHF 6.51B 26M 2023-06
Sarepta Therapeutics USD 120.89M 2.33M 2023-09
Vertex Pharmaceuticals USD 263.8M 1.2M 2023-09



Enanta Pharmaceuticals Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2024.